The Price of Distress Sales
This article was originally published in Start Up
Executive Summary
The small-cap intra-biotech M&A deals now occurring are, at least for sellers, always transactions of last resort--done at extraordinarily dilutive prices. Big Biotech acquisitions, on the other hand, are done for big premiums. In this column, we show the various discounts and premiums biotech acquirers are paying.